Exhibit 10.1

    

    

    

    
      EXECUTIVE EMPLOYMENT AGREEMENT

      BROOKLYN IMMUNOTHERAPEUTICS, INC.

       

      This EXECUTIVE EMPLOYMENT AGREEMENT (this “Agreement”) dated as of June 5, 2021, is entered by and between Brooklyn ImmunoTherapeutics,
        Inc., a Delaware corporation (the “Company”), and Kevin D’Amour, PhD (“Executive”) and will be effective as of June 28, 2021
        (the “Effective Date”).  Each of the Company and Executive are a “Party,” and collectively, they are the “Parties.”

       

      WHEREAS, the Company wishes to employ Executive as of the Effective Date; and

       

      WHEREAS, Executive wishes to be employed by the Company as of the Effective Date.

       

      NOW THEREFORE, in consideration of the above recitals, which are incorporated herein, the mutual covenants and mutual benefits set forth herein, and other good and valuable consideration, the
        receipt and sufficiency of which is acknowledged, the Company and Executive agree as follows:

       

      1.        Representations and Warranties.  Executive represents and warrants to the Company that Executive is not
        bound by any restrictive covenants or other obligations or commitments of any kind that would in any way prevent, restrict, hinder or interfere with Executive’s acceptance of employment under the terms and conditions set forth herein or the
        performance of all duties and services hereunder to the fullest extent of Executive’s ability and knowledge.  Executive understands and acknowledges that Executive is not expected or permitted to use or disclose confidential information belonging
        to any prior employer in the course of performing Executive’s duties for the Company.

       

      2.           Term of Employment.  As of the Effective Date, the Company will employ Executive and Executive accepts
        employment by the Company on the terms and conditions herein that shall commence on the Effective Date and shall continue until terminated pursuant to Section 5 (the “Employment Period”). 
        Notwithstanding anything set forth in Section 5 and for the avoidance of doubt, Executive’s employment is on an at-will basis, meaning that Executive or the Company can terminate Executive’s employment at any time for any reason or no reason, with
        or without notice.  The at-will nature of Executive’s employment cannot be changed except by written agreement signed by Executive and the Company.

       

      3.            Duties and Functions.

       

      (a)       Executive shall be employed as the Chief Scientific Officer of the Company (“CSO”) and shall report to the Chief Executive Officer/President (the “Supervisor”).

       

      (b)        Executive agrees to undertake the duties and responsibilities inherent in the position of CSO, which may encompass different or additional duties as may, from time to time, be assigned
        by his Supervisor, or the Supervisor’s designee, and the duties and responsibilities undertaken by Executive may be altered or modified from time to time by Supervisor, or by the Supervisor’s designee.  Executive’s duties shall include but not be
        limited to those duties set forth on Addendum A.  Executive agrees to abide by the rules, regulations, instructions, personnel practices and policies of the Company and any change thereof which may be adopted at any time by the Company.
        Notwithstanding the foregoing, during the COVID-19 pandemic, business related travel will be subject to the Supervisor’s and Executive’s good faith determination that business related travel is necessary.  All applicable COVID-19 travel
        restrictions, state, local and federal health and safety guidelines, and Company policies should be considered in connection with any travel activities.

       

      
        
          


      

      
      During the Employment Period, Executive will devote Executive’s full time and efforts to the business of the Company and will not, without the consent of the Company, engage in consulting work or any trade or business
        for Executive’s own account or for or on behalf of any other person, firm or corporation that competes, conflicts or interferes with the performance of Executive’s duties hereunder in any way.  However, Executive is permitted to engage in the
        activities listed in Addendum D, pursuant to the terms set forth in Addendum A and to the extent that he is not in violation of the terms of this Agreement or in breach of his fiduciary duties to the Company.

      

      

      4.            Compensation.

       

      (a)          Base Salary:  As compensation for Executive’s services hereunder, the Company agrees to pay Executive a base salary at an annual rate of $415,000, payable in accordance with the
        Company’s normal payroll schedule, but in no event less frequently than monthly.  Executive’s base salary shall be reviewed annually by the Board or the Compensation Committee thereof and subject to increase from time to time in the Board’s and/or
        the Compensation Committee’s sole discretion.

       

      (b)        Bonus:  Beginning with calendar year 2021, Executive shall be eligible to receive an annual cash bonus award in an amount to target 40% of his base salary upon achievement of
        reasonable performance targets set by the Board or the Compensation Committee thereof in its sole discretion.  Such targets shall be based in part upon performance of the Company, and in part on Executive’s individual performance. The bonus shall
        be determined by the Board or the Compensation Committee thereof in its sole discretion and paid annually by March 15 of the year following the performance year on which such bonus is based.  Except as contemplated by Section 5(c)(i) below,
        Executive’s receipt of the bonus, if any, is conditioned on Executive’s continued employment in good standing as of the date on which such bonus is paid, and any such bonus will not be considered earned until such payment date. Executive’s bonus
        opportunity shall be reviewed annually by the Board or the Compensation Committee thereof and subject to adjustment to reflect Executive’s performance in the Board’s and/or the Compensation Committee’s sole discretion. Executive’s bonus for 2021
        shall be prorated for the number of days of employment in calendar year 2021 from the Effective Date.

       

      (c)          Equity Compensation:

       

      (i)          On the Effective Date, in accordance with the employment inducement grant rules set forth in Section 711(a) of the NYSE American LLC Company Guide, Executive shall be granted two
        equity awards covering the Company’s common stock (collectively, the “Grant”). The Grant shall have a grant date fair value for accounting purposes of $5,763,000 (the “Grant Value”) and shall be apportioned among the two equity awards as set forth below using a 30-day volume-weighted average stock price as of the grant date and a restricted stock
        unit-to-option conversion factor of a stock option award covering two shares to a restricted stock unit award covering one share.

       

      
        2

        
          


      

      (ii)         The Company shall grant Executive a time-based nonqualified stock option grant (the “Option Grant”) covering a number of
        shares corresponding to one-half of the Grant Value using the methodology described above in Section 4(c)(i). The per share exercise price of the Option Grant shall equal the closing price of a share of the Company’s common stock on the grant date.
        The Option Grant shall vest as to twenty-five percent of the shares covered thereby on the first anniversary of the Effective Date, and 1/36 of the remaining shares covered thereby on each monthly anniversary of the Effective Date thereafter, in
        each case subject to Executive’s continued employment with the Company through the relevant vesting date. If the number of shares covered by the Option Grant using the methodology described above in Section 4(c)(i) is less than 115,020 shares, such
        number of shares shall be increased to 115,020 shares. If the number of shares covered by the Option Grant using the methodology described above in Section 4(c)(i) is greater than 140,580 shares, such number of shares shall be decreased to 140,580
        shares.

       

      (iii)       The Company shall grant Executive a time-based restricted stock unit grant (the “RSU Grant”) covering a number of shares of
        the Company’s common stock corresponding to one-half of the Grant Value using the methodology described above in Section 4(c)(i). The RSU Grant shall vest in four equal annual installments beginning on the first anniversary of the Effective Date,
        subject to Executive’s continued employment with the Company through the relevant vesting date, and shall be settled by March 15 of the year following the relevant vesting date. If the number of shares covered by the RSU Grant using the methodology
        described above in Section 4(c)(i) is less than 57,510 shares, such number of shares shall be increased to 57,510 shares. If the number of shares covered by the RSU Grant using the methodology described above in Section 4(c)(i) is greater than
        70,290 shares, such number of shares shall be decreased to 70,290 shares.

       

      (iv)        All other terms and conditions of the Option Grant and the RSU Grant shall be the same as the Company’s standard forms of grant agreements.  The Option Grant and the RSU Grant are each
        intended to constitute an “employment inducement grant” in accordance with the employment inducement grant rules set forth in Section 711(a) of the NYSE American LLC Company Guide, and are offered as an inducement material to Executive in
        connection with the Company’s hiring of Executive.

       

      (v)         Commencing in 2022, Executive shall be eligible to receive an equity award under the applicable equity incentive plan of the Company as then in effect, as determined by the
        Compensation Committee based on Executive’s performance.

       

      (d)         Other Expenses:  In addition to the compensation provided for above, the Company agrees to pay or to reimburse Executive during Executive’s employment for all reasonable,
        ordinary and necessary, properly documented, business expenses incurred in the performance of Executive’s services hereunder in accordance with Company policy in effect from time to time; provided, however, that the amount available to Executive
        for such travel, entertainment and other expenses may require advance approval from his Supervisor.  Executive shall submit vouchers and receipts for all expenses for which reimbursement is sought.  Notwithstanding any expense reimbursement policy
        of the Company that may then be in effect, Executive shall be entitled to reimbursement without advance approval by his Supervisor of the costs of (i) up to 4 professional conferences in an amount not to exceed $10,000 annually and (ii) all
        flights, which, when possible, shall be business class or better for all flights for Company travel over three hours in length.  Executive shall also receive $50/month for costs associated with using his mobile device and home internet for business
        purposes pursuant to the Company’s Work From Home Device Use and Reimbursement Policy.

       

      
        3

        
          


      

      (e)         Paid Time Off and Paid Holidays:  Executive shall accrue up to 20 days of paid time off (“PTO”) per year of
        employment, which shall accrue pro rata in the Company’s regular payroll (up to a maximum of 42 days).  PTO shall accrue pro rata in the Company’s regular payroll on a calendar basis and shall be subject to the Company’s PTO policies in place from
        time to time and all applicable state and local law.

       

      Any accrued, unused PTO can be carried over to the following calendar year up to a maximum of 60 days (the “Cap”).   Once the Cap is reached, no further PTO will accrue until some accrued time is
        used.  When some PTO is used, PTO will begin to accrue again.  A portion of accrued, unused PTO may be paid upon separation of employment pursuant to Company policy and applicable law.

       

      In addition to the enumerated paid Company holidays, Executive shall also be entitled to up to seven (7) paid floating holidays per calendar year.  Unused paid floating holidays shall expire on
        December 31 each year and shall not be paid upon separation.

       

      Executive may also be entitled to additional paid or unpaid leave under Company policy and applicable law.

       

      (f)        Fringe Benefits.  In addition to Executive’s compensation provided by the foregoing, Executive shall be entitled to all benefits available generally to Company employees pursuant
        to Company programs which may now or, if not terminated, shall hereafter be in effect, or that may be established by the Company, as and to the extent any such programs are or may from time to time be in effect, as determined by the Company and the terms hereof, subject to the applicable terms and conditions of the benefit plans in effect at that time.  Nothing herein shall affect the Company’s ability to modify, alter, terminate or otherwise
        change any benefit plan it has in effect at any given time, to the extent permitted by law.

       

      (g)         Reimbursements.  With respect to any reimbursement of expenses of Executive, such reimbursement of expenses shall be subject to the following conditions: (i) the expenses
        eligible for reimbursement in one taxable year shall not affect the expenses eligible for reimbursement in any other taxable year; (ii) the reimbursement of an eligible expense shall be made no later than the end of the year after the year in which
        such expense was incurred; and (iii) the right to reimbursement shall not be subject to liquidation or exchange for another benefit.

       

      

      
        4

        
          


      

      5.            Termination.

       

      (a)        Termination by Executive. Executive may terminate the employment relationship at any time by giving the Company written notice, with such termination taking effect upon written
        notice of the termination being provided to the Company. If Executive chooses to terminate the employment relationship other than for Good Reason (defined below), Executive will not be entitled to and shall not receive any compensation or benefits
        of any type following the effective date of termination, other than (i) payment of base salary through the last day of employment, (ii) payment for any accrued but unused paid time off consistent with this agreement and the Company’s policies then
        in effect, (iii) reimbursement for unreimbursed business expenses properly incurred by Executive, which shall be subject to and paid in accordance with the Company’s expense reimbursement policy, and (iv) any right to continued benefits required by
        law or under the Company’s employee benefit plans and vested as of the termination date (the “Accrued Obligations”). If Executive terminates the employment relationship for Good Reason (defined below), Executive will be entitled to the Accrued
        Obligations and the Non-CIC Termination Compensation or CIC Termination Compensation, as applicable and described below, subject to the terms, conditions and restrictions set forth in Section 5(c)(ii).

       

      (i)          “Good Reason” means the occurrence of any of the following without Executive’s express written consent: (A) a material
        reduction in Executive’s base salary or maximum annual bonus, in each case set forth in Section 4; (B) a relocation of Executive to a facility or location that is more than fifty (50) miles from Executive’s primary place of employment as of the
        Effective Date and represents a material increase in Executive’s commuting distance; (C) a material diminution in Executive’s authority, position, duties, or responsibilities individually or taken as a whole and including any such diminution that
        takes place following a Change in Control; or (D) a material breach by the Company of the terms of this Agreement or any other agreement between the Company and Executive; provided, that no such event described above will constitute Good Reason
        unless: (x) Executive gives notice to the Company specifying the condition or event relied upon for such termination within sixty (60) days of the initial existence of such event; and (y) the Company fails to cure the condition or event
        constituting Good Reason within thirty (30) days following receipt of such notice (the “Cure Period”).  If the Company fails to remedy the condition constituting Good Reason during the
        applicable Cure Period, Executive’s termination of employment must occur, if at all, within ninety (90) days following the last day of such Cure Period in order for such termination as a result of such condition to constitute a termination for Good
        Reason.  For purposes of this Agreement, “Change in Control” means as defined in the Company’s 2020 Stock Incentive Plan.

       

      (b)          Termination by Company for Cause.

       

      (i)        At any time during the Employment Period, the Company may terminate Executive’s employment for Cause (defined below), with such termination taking effect upon the later of written
        notice of the termination for Cause being provided to Executive or the expiration of any applicable cure period related thereto (provided that Executive may be relieved from his duties hereunder during such cure period in the reasonable direction
        of the Board).  If Executive’s employment is terminated for Cause, Executive will not be entitled to and shall not receive any compensation or benefits of any type following the effective date of termination, other than the Accrued Obligations, and
        shall forfeit the Option Grant and the RSU Grant, in each case whether vested or unvested.

       

      
        5

        
          


      

      (ii)         “Cause” shall be defined as termination for: (A) in connection with Executive’s services
          hereunder, Executive commits a material act of fraud or material act of dishonesty with respect to the Company, which act causes (or could reasonably be expected to cause) material economic or material reputational harm to the Company; (B)
          Executive is convicted of (or pleads guilty or nolo contendere to) a felony or a crime involving moral turpitude, which demonstrably causes material economic or material reputational harm to the Company; (C) Executive engages in negligence or
          willful misconduct in the performance of his duties hereunder that materially violates the Company’s policies and which misconduct causes (or could reasonably be expected to cause) material economic or material reputational harm to the Company;
          (D) Executive willfully refuses to follow the lawful written directions of his Supervisor, the Supervisor’s designee, or the Board; (E) Executive materially breaches any material provision of any proprietary information and inventions agreement
          with the Company; or (F) Executive breaches any Restrictive Covenant as defined in Section 5(c)(ii).  Notwithstanding anything in this Agreement or elsewhere to the contrary, if an event or occurrence that is alleged to constitute Cause is
          curable (as determined by the Board in good faith), the Company may terminate Executive’s employment for Cause only if (x) the Company gives Executive notice of termination prior to the termination and within thirty (30) days after the Board
          learns of the event or occurrence that is alleged to constitute Cause, specifying the grounds upon which Cause is alleged, (y) Executive fails to cure such grounds for Cause within thirty (30) days after Executive receives such notice, and (z)
          the termination occurs within sixty (60) days after such event or occurrence.  For purposes of this Agreement, no act or failure to act, on Executive’s part, will be considered “willful” unless it is done, or omitted to be done, by Executive in
          bad faith or without reasonable belief that Executive’s action or omission was in the best interests of the Company.

       

      (c)          Termination by Company Without Cause.

       

      (i)        The Company may terminate Executive without Cause immediately by giving Executive written notice of such termination.  Subject to the conditions set forth in Section 5(c)(ii), if
        Executive’s employment is terminated by the Company without Cause, in addition to the Accrued Obligations, Executive shall be entitled to (i) continued base salary for nine (9) months following date of such termination (the “Severance Period”) paid pursuant to the Company's normal practices; and (ii) if Executive and/or Executive’s covered dependents timely elect(s) to receive health care continuation coverage
        pursuant to COBRA, the total monthly cost of coverage for Executive (and such covered dependents) during the Severance Period, provided, for the avoidance of doubt, that such covered dependents participated in the Company’s health plans prior to
        such termination, and provided, further, that if at any time the Company determines that its payment of Executive’s (or Executive’s eligible dependents’) premiums would result in a violation of law, then in lieu of providing the premiums described
        above, the Company will instead pay Executive a fully taxable monthly cash payment in an amount equal to the applicable premiums for such month, with such monthly payment being made on the last day of each month for the remainder of the Severance
        Period (together, the “Non-CIC Termination Compensation”). Notwithstanding the foregoing, if Executive’s employment is terminated by the Company without Cause or by Executive for Good
        Reason, in each case during the ninety (90) days prior to or twelve (12) month period following a Change in Control, (i) the Executive shall receive the Non-CIC Termination Compensation as described above except that the Severance Period shall
        equal twelve (12) months in lieu of nine (9) months, (ii) Executive shall receive a lump-sum payment of Executive’s target annual bonus and (iii) Executive shall become fully vested in the Option Grant and the RSU Grant (together, the “CIC Termination Compensation”). The Non-CIC Termination Compensation and the CIC Termination Compensation shall, as applicable and in each case, be subject to the terms, conditions and
        restrictions set forth below in Section 5(c)(ii).

       

      
        6

        
          


      

      (ii)        Executive shall not be entitled to any Non-CIC Termination Compensation or CIC Termination Compensation unless (A) Executive complies with all surviving provisions of any
        non-competition agreement, non-solicitation agreement, or confidentiality agreement or invention assignment agreement signed by Executive, including those contained in this Agreement (the “Restrictive

          Covenants”) and (B) Executive executes and delivers to the Company, and does not revoke a separation agreement and general release in form and substance acceptable to the Company within thirty (30) days after Executive’s separation date,
        by which Executive releases the Company from any obligations and liabilities of any type whatsoever, except for the Company’s obligations with respect to, as applicable, the Non-CIC Termination Compensation or the CIC Termination Compensation (the
        “Release”).  Such Release shall not affect Executive’s right to indemnification, if any, for actions taken within the scope of Executive’s employment. The Non-CIC Termination Compensation
        or the CIC Termination Compensation, as applicable, shall begin, or if lump-sum, be paid on the first payroll following the Release becoming irrevocable; provided, however, if the thirty (30) day period during which Executive has discretion to
        execute or revoke the Release straddles two taxable years of Executive, then the Company shall pay the Non-CIC Termination Compensation or the CIC Termination Compensation, as applicable, starting in the second of such taxable years, regardless of
        which taxable year Executive actually delivers the executed Release to the Company.  The Parties hereto acknowledge that the Non-CIC Termination Compensation and the CIC Termination Compensation, as applicable, to be provided under Section 5(c)(i)
        is to be provided in consideration for the above-specified Release.  If Executive breaches any of the Restrictive Covenants at any time during the Severance Period, (1) the Company will have no further obligation to pay Executive any unpaid Non-CIC
        Termination Compensation or CIC Termination Compensation, as applicable, (2) Executive must repay any portion of the Non-CIC Termination Compensation or the CIC Termination Compensation, as applicable, already paid to him, and (3) the Company may
        take any additional action to enforce its rights under the Restrictive Covenants.  Finally, if Executive becomes employed during the Severance Period, Executive will no longer be entitled to receive his continued base salary from the Company.

       

      (iii)       Disqualification for Other Severance.  The Non-CIC Termination Compensation and the CIC Termination Compensation described in this Section 5(c) is intended to supersede any
        other similar compensation provided by any Company policy, plan or practice.  Therefore, Executive shall be disqualified from receiving any similar compensation under any other Company severance policy, plan or practice, if any. Notwithstanding the
        foregoing, Executive shall continue to be eligible for any benefits pursuant to the terms of any health or retirement plan sponsored by the Company, subject to and in accordance with the terms of the applicable plan.

       

      (d)         Termination for Executive’s Permanent Disability.  To the extent permissible under applicable law, in the event Executive becomes permanently disabled during employment with the
        Company, the Company may terminate this Agreement by giving thirty (30) days' notice to Executive of its intent to terminate, and unless Executive resumes performance of the duties set forth in Section 3 within five (5) days of the date of the
        notice and continues performance for the remainder of the notice period, this Agreement shall terminate at the end of the thirty (30) day period.  For purposes of this Agreement, “permanently disabled” shall mean if Executive is considered totally
        disabled under any group disability plan maintained by the Company and in effect at that time, or in the absence of any such plan, under applicable Social Security regulations, to the extent not inconsistent with applicable law.  In the event of
        any dispute under this Section 5(d), Executive shall submit to a physical examination by a licensed physician mutually satisfactory to the Company and Executive, the cost of such examination to be paid by the Company, and the determination of such
        physician shall be determinative.  In the event the Executive is terminated pursuant to this Section 5(d), Executive will be entitled to the Accrued Obligations and the Non-CIC Termination Compensation, subject to the terms, conditions and
        restrictions set forth in Section 5(c)(ii).

       

      
        7

        
          


      

      (e)         Termination Due to Executive’s Death.  This Agreement will terminate immediately upon Executive’s death and the Company shall not have any further liability or obligation to
        Executive, Executive’s executors, heirs, assigns or any other person claiming under or through Executive’s estate, except that Executive’s estate shall receive any Accrued Obligations. In addition, Executive’s estate shall be entitled to
        accelerated vesting of the portion of the Option Grant and the RSU Grant that would have otherwise vested during the nine (9) month period following such termination.

       

      (f)         Continuing Obligations.  The obligations imposed on Executive with respect to non-competition, non-solicitation, confidentiality, non-disclosure and assignment of rights to
        inventions or developments in this Agreement or any other agreement executed by the Parties shall continue, notwithstanding the termination of the employment relationship between the Parties and regardless of the reason for such termination.

       

      6.           Company Property.  All correspondence, records, documents, software, promotional materials, and other
        Company property, including all copies, which come into Executive’s possession by, through or in the course of Executive’s employment, regardless of the source and whether created by Executive, are the sole and exclusive property of the Company,
        and immediately upon the termination of Executive’s employment, or at any time the Company shall request, Executive shall return to the Company all such property of the Company, without retaining any copies, summaries or excerpts of any kind or in
        any format whatsoever.  Executive shall not destroy any Company property, such as by deleting electronic mail or other files, other than in the normal course of Executive’s employment.  Executive further agrees that should Executive discover any
        Company property or Confidential Information in Executive’s possession after the return of such property has been requested, Executive agrees to return it promptly to Company without retaining copies, summaries or excerpts of any kind or in any
        format whatsoever.

       

      7.            Non-Competition and Non-Solicitation.

       

      (a)        Executive agrees and acknowledges that, in connection with Executive’s employment with the Company, Executive will be provided with access to and become familiar with confidential and
        proprietary information and trade secrets belonging to the Company and its affiliates.  Accordingly, in consideration of Executive’s employment with the Company pursuant to this Agreement, and other good and valuable consideration, the receipt of
        which is hereby acknowledged, Executive agrees that, while Executive is in the employ of the Company and/or any of its affiliates, Executive shall not, either on Executive’s own behalf or on behalf of any third party, except on behalf of the
        Company or one of its affiliates, directly or indirectly:

       

      
        8

        
          


      

      (i)          engage directly or indirectly in the Business (as defined below) anywhere in the Restricted Territory (as defined below) or directly or indirectly be or become an
        officer, director, stockholder, owner, affiliate, partner, member, investor, joint venture, employee, agent, representative, consultant, lender, advisor, manager of, for or to, or otherwise be or become associated with or acquire or hold (of
        record, beneficially or otherwise) any direct or indirect interest in, any business or enterprise engaged directly or indirectly in the Business (as defined below) anywhere in the Restricted Territory (as defined below).  As used herein, (A) the
        term “Business” shall mean the business of development and manufacturing of a cytokine immunotherapy (related to or derived from human source material) for cancer treatment and RNA based
        gene therapy and editing of MSC, HSC, TILs and T-Cells, and (B) the term “Restricted Territory” shall mean worldwide.  The foregoing restriction shall not be construed to prohibit the
        ownership by Executive as a passive investment of shares of capital stock of a publicly-held corporation that engages in the Business if (x) such shares are actively traded on an established national securities market in the United States or any
        other foreign securities exchange, (y) the number of shares of such corporation’s capital stock that are owned beneficially (directly or indirectly) by Executive and the number of shares of such corporation’s capital stock that are owned
        beneficially (directly or indirectly) by Executive’s affiliates collectively represent less than one percent (1%) of the total number of shares of such corporation’s capital stock outstanding, and (z) neither Executive nor any affiliate of
        Executive is otherwise associated directly or indirectly with such corporation or with any affiliate of such corporation;

       

      (ii)        attempt in any manner to solicit, induce or attempt to induce any business, enterprise, or individual who has a business relationship with the Companies (including
        any customer, licensee, supplier, manufacturer or vendor) (x) to cease doing business with the Company or any of its affiliates, (y) to diminish or materially alter in a manner harmful to the Company or any of its
        affiliates, or any of their affiliates such business, enterprise, or individual’s relationship with the Company or any of its affiliates, or (z) to purchase, contract for or receive any products or services from any business or enterprise (other
        than the Company or any of its affiliates) that engages in the Business anywhere within the Restricted Territory; or

       

      (b)        Executive agrees and acknowledges that for one (1) year period following the end of Executive’s employment for any reason,  Executive shall not, either on Executive’s own behalf or on
        behalf of any third party (A) directly or indirectly hire any employee, independent contractor, or consultant or any person who was an employee, independent contractor, or consultant of the Companies within the preceding six (6) months, or (B)
        directly or indirectly encourage, induce, attempt to induce, solicit or attempt to solicit (on Executive’s own behalf or on behalf of any other business, enterprise, or individual) any employee, independent contractor, or consultant to leave or
        curtail his or her employment or engagement with the Company or any of its affiliates; provided, however, that notwithstanding the foregoing, this Section 7(a)(iii) shall not prevent Executive from undertaking general solicitations of employment
        not targeted at employees, independent contractors, or consultants of the Company or any of its affiliates (so long as Executive does not, directly or indirectly, hire any such employee, independent contractor, or consultant).

       

      
        9

        
          


      

      (c)        The Parties agree that the relevant public policy aspects of post-employment restrictive covenants have been discussed, and that every effort has been made to limit the restrictions
        placed upon Executive to those that are reasonable and necessary to protect the Company’s legitimate interests.  Executive acknowledges that, based upon Executive’s education, experience, and training, the restrictions set forth in this Section 7
        will not prevent Executive from earning a livelihood and supporting himself and Executive’s family during the relevant time period.  Executive further acknowledges that, because the Company markets its products and services throughout the
        Restricted Territory, a more narrow geographic limitation on the restrictive covenants set forth above would not adequately protect the Company’s legitimate business interests.

       

      (d)          If any restriction set forth in this Section 7 is found by any court of competent jurisdiction or arbitrator to be unenforceable because it extends for too long a period of time or
        over too great a range of activities or geographic area, it shall be interpreted to extend over the maximum period of time, range of activities or geographic area as to which it may be enforceable.

       

      (e)        The restrictions contained in Section 7 are necessary for the protection of the business and goodwill of the Company and/or its affiliates and are considered by Executive to be
        reasonable for such purposes.  Executive agrees that any material breach of Section 7 will result in irreparable harm and damage to the Company and/or its affiliates that cannot be adequately compensated by a monetary
        award.  Accordingly, it is expressly agreed that in addition to all other remedies available at law or in equity (including, without limitation, money damages from Executive), the Company and/or such affiliate shall be entitled to a temporary
        restraining order, preliminary injunction or such other form of injunctive or equitable relief as may be issued by any court of competent jurisdiction or arbitrator to restrain or enjoin Executive from breaching any such covenant or provision or to
        specifically enforce the provisions hereof, without the need to post any bond or other security.

       

      (f)        The existence of a claim, charge, or cause of action by Executive against the Company shall not constitute a defense to the enforcement by the Company of the foregoing restrictive
        covenants.

       

      (g)          The provisions of this Section 7 shall apply regardless of the reason for the termination of Executive’s employment.

       

      8.           Non-Circumvention / Non-Interference.  Executive acknowledges and agrees that during the Employment
        Period, Executive shall not, and shall not authorize or permit any of his Representatives to, directly or indirectly, interfere, discuss, contact, initiate, or engage, encourage, solicit, initiate, facilitate or continue inquiries to any third
        parties concerning any business opportunities related to the Company.  It is understood that, during the Employment Period, without previous written consent from the Company, the Executive  will not enter, either directly or indirectly, into any
        discussions, solicit or accept offers, enter into any agreements, conduct negotiations with or otherwise engage in any other independent communications with: any third party to whom Executive was introduced to by any member, shareholder, officer,
        director, employee, agent, customer, supplier, vendor, or other representative of the Company, Factor Bioscience, or Novellus, Inc.; any third party to whom Executive was informed of by any member, shareholder, officer, director, employee, agent,
        customer, supplier, vendor, or other representative of Company, Factor Bioscience, or Novellus, Inc. or any employee, financial partner, investor, contractor of the Company. For purposes of this Agreement, "Representatives" means, as to Company,
        its affiliates, and respective consultants (including attorneys, financial advisors and accountants).  Further, after termination of Executive’s employment with the Company, he will not interfere with existing contractual and or business
        relationships with the Company in a manner prohibited by law.

       

      
        10

        
          


      

      9.           Protection of Confidential Information.

       

      (a)        Executive agrees that all information, whether or not in writing, relating to the business, technical or financial affairs of the Company and that is generally understood in the industry
        as being confidential and/or proprietary information, is the exclusive property of the Company.  Executive agrees to hold in a fiduciary capacity for the sole benefit of the Company all secret, confidential and/or proprietary information,
        knowledge, and data, including trade secrets, relating to the Company or any of its affiliates obtained during Executive’s employment with the Company or any of its predecessors or affiliates, including but not limited to any trade secrets,
        confidential or secret designs, website technologies, content, processes, formulae, plans, manuals, devices, machines, know-how (including without limitation the manufacturing of IRX-2), methods, compositions, ideas, improvements, financial and
        marketing information, costs, pricing, sales, sales volume, salaries, methods and proposals, customer and prospective customer lists, customer identities, customer volume, or customer contact information, identity of key personnel in the employ of
        customers and prospective customers, amount or kind of customer’s purchases from the Companies or their affiliates, manufacturer lists, manufacturer identities, manufacturer volume, or manufacturer contact information, identity of key personnel in
        the employ of manufacturers, amount or kind of the Companies’ or their affiliates’ purchases from manufacturers, system documentation, hardware, engineering and configuration information, computer programs, source and object codes (whether or not
        patented, patentable, copyrighted or copyrightable), related software development information, inventions or other confidential or proprietary information (including without limitation information relating to IRX-2 and its intellectual property
        that has not yet issued) belonging to the Companies or their affiliates or directly or indirectly relating to the Companies’ or their affiliates’ business and affairs (“Confidential Information”). 

        Executive agrees that Executive will not at any time, either during the Employment Period or the Confidentiality Period (as defined below), disclose to anyone any Confidential Information, or utilize such Confidential Information for Executive’s
        own benefit, or for the benefit of third parties without written approval by an officer of the Company.  For purposes of this section, the “Confidentiality Period” means so long as such
        information, data, or material remains confidential.  Executive further agrees that all memoranda, notes, records, data, schematics, sketches, computer programs, prototypes, or written, photographic, magnetic or other documents or tangible objects
        compiled by Executive or made available to Executive during the Employment Period concerning the business of the Company and/or its clients, including any copies of such materials, shall be the property of the Company and shall be delivered to the
        Company on the termination of Executive’s employment, or at any other time upon request of the Company.

       

      

      
        11

        
          


      

      (b)        In the event Executive is questioned by anyone not employed by the Company or by an employee of or a consultant to the Company not authorized to receive such information, in regard to
        any Confidential Information or any other secret or confidential work of the Company, or concerning any fact or circumstance relating thereto, or in the event that Executive becomes aware of the unauthorized use of Confidential Information by any
        party, whether competitive with the Company or not, Executive will promptly notify an executive officer of the Company.

       

      

      (c)        Confidential and Proprietary Information of Others. Executive acknowledges that the Company has a strict policy against using confidential or proprietary information belonging to
        any other person or entity without the express permission of the owner of that information. Executive represents and warrants that the performance by Executive of all of the terms of this Agreement will not result in any breach of any duty owed by
        Executive to ViaCyte, Inc. or any other third party to keep in confidence or not to use any confidential or proprietary information, knowledge or data acquired by Executive in confidence. Executive agrees not to disclose to the Company or to induce
        the Company to use any confidential or proprietary information belonging to any third party. Executive will not, at any time, disclose to, or discuss with, the Company employees any confidential or proprietary data belonging to Executive’s former
        employers, nor will Executive bring to the Company’s premises any confidential or proprietary information belonging to Executive’s former employers, ViaCyte, Inc., or any other third party, and will not disclose or use any such information while
        performing work for the Company. Executive agrees to indemnify and hold harmless the Company for any damages whether monetary, punitive, or in equity caused by or the result of Executive’s disclosure of confidential or proprietary information or
        any confidential information belonging to Executive’s former employers, ViaCyte, Inc., or other entities or persons with whom Executive has a duty to not disclose confidential or proprietary information.

       

      (d)       Court-Ordered Disclosure.  In the event that, at any time during Executive’s employment with the Company or at any time thereafter, Executive receives a request to disclose  any
        Confidential Information under the terms of a subpoena or order issued by a court or by a governmental body, Executive agrees to notify the Company immediately of the existence, terms, and circumstances surrounding such request, to consult with the
        Company on the advisability of taking legally available steps to resist or narrow such request; and, if disclosure of such Confidential Information is required to prevent Executive from being held in contempt or subject to other penalty, to furnish
        only such portion of the Confidential Information as, in the written opinion of counsel satisfactory to the Company, Executive is legally compelled to disclose, and to exercise Executive’s best efforts to obtain an order or other reliable assurance
        that confidential treatment will be accorded to the disclosed Confidential Information.

       

      (e)        Defend Trade Secrets Act.  Pursuant to the Defend Trade Secrets Act of 2016, Executive acknowledges that Executive shall not have criminal or civil liability under any federal or
        state trade secret law for the disclosure of a trade secret that (A) is made (i) in confidence to a federal, state, or local government official, either directly or indirectly, or to an attorney and (ii) solely for the purpose of reporting or
        investigating a suspected violation of law; or (B) is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal. In addition, if Executive files a demand for arbitration alleging retaliation by
        the Company for reporting a suspected violation of law, Executive may disclose the trade secret to Executive’s attorney and may use the trade secret information in the arbitration proceeding, if Executive (X) files any document containing the trade
        secret under seal and (Y) does not disclose the trade secret, except pursuant to an order of the arbitrator.

       

      
        12

        
          


      

      10.          Intellectual Property.

       

      (a)          Disclosure of Inventions.  Executive will promptly disclose in confidence to the Company all inventions, improvements, processes, products, designs, original works of
        authorship, formulas, processes, compositions of matter, computer software programs, Internet products and services, e-commerce products and services, e-entertainment products and services, databases, mask works, trade secrets, product
        improvements, product ideas, new products, discoveries, methods, software, uniform resource locators or proposed uniform resource locators (“URLs”), domain names or proposed domain names,
        any trade names, trademarks or slogans, which may or may not be subject to or able to be patented, copyrighted, registered, or otherwise protected by law (the “Inventions”) that Executive
        makes, conceives or first reduces to practice or creates, either alone or jointly with others, during the period of Executive’s employment, whether or not in the course of Executive’s employment (i) that result from any work performed by the
        Executive for the Company; (ii) that are developed from using the Company's equipment, supplies, facilities or trade secret information; or (iii) that relate at the time of conception or reduction to practice of the invention to the Company's
        business, or actual or demonstrably anticipated research or development of the Company.  The requirements of this Section 10(a) shall not apply to any Inventions that qualify fully under the provisions of California Labor Code section 2870 (the
        terms of which are set forth on Addendum B to this Agreement), specifically, any Invention that Executive developed entirely on Executive’s own time without using the Employer’s equipment, supplies, facilities, or trade secret information
        except for those Inventions that either (i) relate at the time of conception or reduction to practice of the Invention to the Employer’s business, or Employer’s actual or demonstrably anticipated research or development; or (ii) result from any
        work performed by Executive for Employer.  Executive shall bear the full burden of proving to the Employer that an Invention qualifies fully under section.  The foregoing requirements of Section 10(a) apply, and whether or not such Inventions are
        patentable, copyrightable or able to be protected as trade secrets, or otherwise able to be registered or protected by law. Executive has provided a list of prior Inventions as Addendum C, which will not be subject to the provisions of this
        Section 10.

       

      (b)         Assignment of Company Inventions; Work for Hire.  Executive agrees that all Inventions that (i) are developed using equipment, supplies, facilities or trade secrets of the
        Company, (ii) result from work performed by Executive for the Company, or (iii) relate to the Company’s business or current or anticipated research and development (the “Company Inventions”),

        will be the sole and exclusive property of the Company and the Executive hereby agrees to irrevocably assign to the Company any such Company Inventions.  Executive further acknowledges and agrees that any copyrightable works prepared by Executive
        within the scope of Executive’s employment are “works for hire” under the Copyright Act and that the Company will be considered the author and owner of such copyrightable works from the moment of their creation and fixation in tangible media.

       

      
        13

        
          


      

      (c)         Assignment of Other Rights.  In addition to the foregoing assignment of Company Inventions to the Company, Executive hereby irrevocably transfers and assigns to the Company: 
        (i) all worldwide patents, patent applications, copyrights, mask works, trade secrets and other intellectual property rights in any Company Invention; and (ii) any and all “Moral Rights” (as defined below) that Executive may have in or with respect
        to any Company Invention.  Executive also hereby forever waives and agrees never to assert any and all Moral Rights Executive may have in or with respect to any Company Invention, even after termination of Executive’s work on behalf of the
        Company.  “Moral Rights” means any rights to claim authorship of an Company Invention, to object to or prevent the modification of any Company Invention, or to withdraw from circulation or
        control the publication or distribution of any Company Invention, and any similar right, existing under judicial or statutory law of any country in the world, or under any treaty, regardless of whether or not such right is denominated or generally
        referred to as a “moral right.”

       

      (d)        Assistance.  Executive agrees to assist the Company in every proper way to obtain for the Company and enforce patents, copyrights, mask work rights, trade secret rights and other
        legal protections for the Company Inventions in any and all countries.  Executive will execute any documents that the Company may reasonably request for use in obtaining or enforcing such patents, copyrights, mask work rights, trade secrets and
        other legal protections.  Executive’s obligations under this section will continue beyond the termination of Executive’s employment with the Company, provided that the Company will compensate Executive at a reasonable rate after such termination
        for time or expenses actually spent by Executive at the Company’s request on such assistance.  Executive appoints the Secretary of the Company as Executive’s attorney-in-fact to execute documents on Executive’s behalf for this purpose.

       

      11.       Publicity; Non-disparagement.  Neither Party shall issue, without consent of the other Party, any press
        release or make any public announcement with respect to this Agreement or the employment relationship between them, or the ending of such relationship.  Following the date of this Agreement and regardless of any dispute that may arise in the
        future, Executive agrees that Executive will not disparage, criticize or make statements which are negative, detrimental or injurious to Company or any of its affiliates, or any of their affiliates to any individual, company or client, including
        within the Company.  This Section 11 does not, in any way, restrict or impede the parties hereto from exercising protected rights to the extent that such rights cannot be waived by agreement or from complying with
        any applicable law or regulation or a valid order of a court of competent jurisdiction or an authorized government agency, provided that such compliance does not exceed that required by the law, regulation, or order.  Nothing contained herein shall
        prevent Executive from providing true testimony to the extent required within any legal proceeding (or in any discovery in connection therewith) or investigation by a governmental authority.

       

      12.      Binding Agreement.  This Agreement shall be binding upon and inure to the benefit of the Parties hereto,
        their heirs, personal representatives, successors and assigns.  Executive acknowledges and agrees that the Company may, in its sole discretion, assign this Agreement (i) to an affiliate of the Company at any time, or (ii) in the event the Company
        is acquired, is a non-surviving party in a merger, or transfers substantially all of its assets, to the transferee or surviving company, in each case without being required to obtain Executive’s consent.  The Parties understand that the obligations
        of Executive are personal and may not be assigned by him.

       

      
        14

        
          


      

      13.       Entire Agreement.  This Agreement contains the entire understanding of Executive and the Company with
        respect to employment of Executive.  This Agreement may not be amended, waived, discharged or terminated orally, but only by an instrument in writing, specifically identified as an amendment to this Agreement, and signed by all Parties.  By
        entering into this Agreement, Executive certifies and acknowledges that Executive has carefully read all of the provisions of this Agreement and that Executive voluntarily and knowingly enters into said Agreement.

       

      14.        Severability.  Any provision of this Agreement which is prohibited or unenforceable in any jurisdiction
        shall, as to such jurisdiction, be deemed severable from the remainder of this Agreement, and the remaining provisions contained in this Agreement shall be construed to preserve to the maximum permissible extent the intent and purposes of this
        Agreement.

       

      15.         Tax Consequences.  If any payment or benefit the Executive would receive pursuant to this Agreement (“Payment”) would (a) constitute a “Parachute Payment” within the meaning of Section 280G of the Code, and (b) but for this sentence,
        be subject to the excise tax imposed by Section 4999 of the Code (the “Excise Tax”), then such Payment shall be equal to the Reduced Amount.  The “Reduced Amount” shall be either (i) the largest portion of the Payment that would result in no portion of the Payment being subject to the Excise Tax or (ii) the largest portion, up to and including the total of the
        Payment, whichever amount, after taking into account all applicable federal, state and local employment taxes, income taxes, and the Excise Tax (all computed at the highest applicable marginal rate), results in the Executive’s receipt, on an
        after-tax basis, of the greatest economic benefit notwithstanding that all or some portion of the Payment may be subject to the Excise Tax.  If a reduction in payments or benefits constituting Parachute Payments is

        necessary so that the Payment equals the Reduced Amount, reduction shall occur in the manner that results in the greatest economic benefit for Executive to the extent permitted by Section 409A of the Code, to the extent applicable, and Section 280G
        of the Code.  Except as otherwise specifically provided in this Agreement, the Company will have no obligation to any person entitled to the benefits of this Agreement with respect to any tax obligation any such person incurs as a result of or
        attributable to this Agreement, including all supplemental agreements and employee benefits plans incorporated by reference therein, or arising from any payments made or to be made under this Agreement or thereunder.  All determinations under this
        Section 15 will be made by an actuarial firm, accounting firm, law firm, or consulting firm experienced and generally recognized in 280G matters (the “280G Firm”) that
        is chosen by the Company prior to a change in ownership or control of a corporation (within the meaning of Treasury regulations under Section 280G of the Code). The 280G Firm shall be required to evaluate the extent to which payments are exempt
        from Section 280G as reasonable compensation for services rendered before or after the Change in Control. All fees and expenses of the 280G Firm shall be paid solely by the Company or its successor. The Company and Executive shall furnish the tax
        firm such information and documents as the tax firm may reasonably request in order to make its required determination.  The 280G Firm will provide its calculations, together with detailed supporting documentation, to the Company and Executive as
        soon as practicable following its engagement.  Any good faith determinations of the 280G Firm made hereunder will be final, binding and conclusive upon the Company and Executive.

       

      
        15

        
          


      

      16.         Withholding.  The Company shall have the right to withhold from any amount payable hereunder any
        federal, state, local and foreign taxes in order for the Company to satisfy any withholding tax obligation it may have under any applicable law or regulation. Notwithstanding any other provision of this Agreement, the Company does not guarantee any
        particular tax result for Executive with respect to any payment provided to Executive hereunder, and Executive shall be solely responsible for any taxes imposed on Executive with respect to any such payment.

       

      17.          Section 409A.

       

      (a)        This Agreement is intended to comply with, or otherwise be exempt from, Section 409A of the Code and any regulations and Treasury guidance promulgated thereunder (“Section 409A of the Code”) and shall be construed and administered in accordance with such intent.  Notwithstanding any other provision of this Agreement, payments provided under this
        Agreement may only be made upon an event and in a manner that complies with Section 409A of the Code or an applicable exemption. Any payments under this Agreement that may be excluded from Section 409A of the Code either as separation pay due to an
        involuntary separation from service or as a short-term deferral shall be excluded from Section 409A of the Code to the maximum extent possible. Notwithstanding the foregoing, the Company makes no representations that the payments and benefits
        provided under this Agreement comply with Section 409A of the Code and in no event shall the Company be liable for all or any portion of any taxes, penalties, interest or other expenses that may be incurred by the Executive on account of
        non-compliance with Section 409A of the Code.

       

      (b)         For purposes of Section 409A of the Code, the right to a series of installment payments under this Agreement shall be treated as a right to a series of separate payments.  In no event
        may Executive, directly or indirectly, designate the calendar year of payment.

       

      (c)       With respect to any reimbursement of expenses of, or any provision of in-kind benefits to, Executive, as specified under this Agreement, such reimbursement of expenses or provision of
        in-kind benefits shall be subject to the following conditions: (1) the expenses eligible for reimbursement or the amount of in-kind benefits provided in one taxable year shall not affect the expenses eligible for reimbursement or the amount of
        in-kind benefits provided in any other taxable year, except for any medical reimbursement arrangement providing for the reimbursement of expenses referred to in Section 105(b) of the Code; (2) the reimbursement of an eligible expense shall be made
        no later than the end of the year after the year in which such expense was incurred; and (3) the right to reimbursement or in-kind benefits shall not be subject to liquidation or exchange for another benefit.

       

      (d)        “Termination of employment,” “resignation,” or words of similar import, as used in this Agreement means, for purposes of any payments under this Agreement that are payments of deferred
        compensation subject to Section 409A of the Code, Executive’s “separation from service” as defined in Section 409A of the Code.

       

      (e)       If a payment obligation under this Agreement arises on account of Executive’s separation from service while Executive is a “specified employee” (as defined under Section 409A of the Code
        and determined in good faith by the Company), any payment of “deferred compensation” (as defined under Treasury Regulation Section 1.409A-1(b)(1), after giving effect to the exemptions in Treasury Regulation Sections 1.409A-1(b)(3) through (b)(12))
        that is scheduled to be paid within six (6) months after such separation from service shall accrue without interest and shall be paid within fifteen (15) days after the end of the six-month period beginning on the date of such separation from
        service or, if earlier, within fifteen (15) days after the appointment of the personal representative or executor of Executive’s estate following Executive’s death.

       

      
        16

        
          


      

      18.        Governing Law.  This Agreement shall be governed by, and construed and enforced in accordance with, the
        laws of New York, without giving effect to the principles of conflicts of law thereof.

       

      19.        Notices.  Any notice provided for in this Agreement shall be provided in writing.  Notices shall be
        effective from the date of service, if served personally on the Party to whom notice is to be given, or on the second day after mailing, if mailed by first class mail, postage prepaid.  Notices shall be properly addressed to the Parties at their
        respective addresses or to such other address as either Party may later specify by notice to the other.

       

      20.          Dispute Resolution.

       

      (a)       Executive and the Company mutually agree that any controversy or claim arising out of or relating to this Agreement or the employment relationship between Executive and the Company,
        including any dispute regarding the scope or enforceability of this arbitration provision, shall be settled by individual arbitration administered by Judicial Arbitration and Mediation Services (JAMS) in accordance with the JAMS Employment
        Arbitration Rules and Procedures in effect as of the date of this Agreement (“JAMS Rules”), to the extent the JAMS Rules are consistent with the terms of this provision. Judgment on the award may be entered in any court having jurisdiction
        thereof.  The parties also mutually agree that, except as otherwise required by enforceable law, arbitration shall be the sole and exclusive forum for resolving such disputes (including any dispute with the Company, any related parties, and any of
        their respective employees, officers, owners or agents, who shall be third-party beneficiaries of this provision), and both parties agree that they are hereby waiving any right to have their disputes resolved in civil litigation by a court or jury
        trial, including but not limited to any disputes arising under statutes such as Title VII of the Civil Rights Act, the Age Discrimination in Employment Act, or the California Fair Employment and Housing Act.  The arbitrator’s decisions on such
        matters shall be final and binding on the parties to the fullest extent permitted by law.  The JAMS Rules are incorporated herein by reference, to the extent they are consistent with the terms of this provision, and may be found at available at
        https://www.jamsadr.com/rules-employment-arbitration/.  The place of arbitration shall be New York County, New York.  Any arbitration hereunder shall be conducted only on an individual basis and not in a class, consolidated, or representative
        action.  The Company shall pay the administrative costs and fees directly related to the arbitration, including the fees of the arbitrator.  Each party shall otherwise bear its own respective attorneys’ fees and costs, including the costs of any
        depositions or for expert witnesses, unless any applicable law provides otherwise to the prevailing party, in which case the arbitrator shall have the authority to award costs and attorneys’ fees to the prevailing party in accordance with the
        applicable law.  Neither a party nor the arbitrator may disclose the existence, content, or results of any arbitration hereunder without the prior written consent of both parties, unless otherwise provided by law.  The parties’ agreement to
        arbitrate does not apply to claims that, pursuant to applicable law, cannot be subject to mandatory arbitration, including claims under the Private Attorney General Act; provided that, in the event of a dispute regarding whether, or the extent to
        which, any dispute is subject to arbitration, the parties agree that no underlying dispute or any facts regarding such dispute shall be submitted to a court until and unless a declaratory judgment is issued by the duly appointed arbitrator that
        allows a dispute to proceed in court based on a claim by a party that this arbitration provision is unenforceable as a matter of law as to an asserted claim.  Moreover, nothing in this Agreement prevents Executive from filing or prosecuting a
        charge with any government agency (such as the Equal Employment Opportunity Commission) over which such agency has jurisdiction, or from participating in an investigation or proceeding conducted by any such agency. Any matter required to be
        arbitrated under this Section 20 shall be submitted to mediation in a manner agreed to by Executive and the Company.  Executive and the Company agree to use mediation to attempt to resolve any such matter prior to filing for arbitration.  Executive
        and the Company will select a mediator agreeable to both parties.  The costs of the mediation and fees of the mediator will be borne entirely by the Company.

       

      
        17

        
          


      

      BY AGREEING TO ARBITRATION, THE PARTIES ACKNOWLEDGE THAT THEY WAIVE THE RIGHT TO BRING AND/OR PARTICIPATE IN ANY CLASS OR COLLECTIVE ACTION. THE ARBITRATOR SHALL HAVE NO POWER TO
        ARBITRATE ANY CLASS AND/OR COLLECTIVE CLAIMS. BY AGREEING TO ARBITRATION, THE PARTIES ACKNOWLEDGE THAT THEY ARE WAIVING THEIR STATUTORY AND COMMON LAW RIGHTS TO SEEK RELIEF IN A COURT OF LAW AND ARE WAIVING THEIR RIGHTS TO A TRIAL BY JURY.

       

      (b)        Notwithstanding the provisions of Section 20(a), the Parties further acknowledge and agree that, due to the nature of the confidential information, trade secrets, and intellectual
        property belonging to the Company to which Executive has or will be given access, and the likelihood of significant harm that the Company would suffer in the event that such information was disclosed to third parties, the Company shall have the
        right to file suit  in a court of competent jurisdiction to seek injunctive relief to prevent Executive from violating the obligations established in Sections 7, 8, 9 or 10 of this Agreement without first submitting the  claim, controversy, or
        dispute to JAMS mediation or arbitration.

       

      21.         Indemnification.  The Company shall indemnify and hold harmless Executive for any liability to any
        third-party incurred by reason of any act or omission performed by Executive while acting in good faith on behalf of the Company and within the scope of the authority of Executive pursuant to this Agreement and under the rules and policies of the
        Company, except that Executive must have in good faith believed that such action was in the best interest of the Company and such course of action or inaction must not have constituted gross negligence, fraud, willful misconduct, or breach of a
        fiduciary duty.

       

      22.          Miscellaneous.

       

      (a)        Compensation Recovery Policy. Executive acknowledges and agrees that, to the extent the Company adopts any claw-back or similar policy pursuant to the Dodd-Frank Wall Street Reform and
        Consumer Protection Act or otherwise, and any rules and regulations promulgated thereunder, he or she shall take all action necessary or appropriate to comply with such policy (including, without limitation, entering into any further agreements,
        amendments or policies necessary or appropriate to implement and/or enforce such policy with respect to past, present and future compensation, as appropriate).

       

      
        18

        
          


      

      (b)         No delay or omission by the Company in exercising any right under this Agreement shall operate as a waiver of that or any other right.  A waiver or consent given by the Company on any
        one occasion shall be effective only in that instance and shall not be construed as a bar or waiver of any right on any other occasion.

       

      (c)          The captions of the sections of this Agreement are for convenience of reference only and in no way define, limit or affect the scope or substance of any section of this Agreement.

       

      (d)         The language in all parts of this Agreement will be construed, in all cases, according to its fair meaning, and not for or against either Party hereto.  The Parties acknowledge that
        each Party and its counsel have reviewed and revised this Agreement and that the normal rule of construction to the effect that any ambiguities are to be resolved against the drafting Party will not be employed in the interpretation of this
        Agreement.

       

      (e)        The obligations of Company under this Agreement, including its obligation to pay the compensation provided for in this Agreement, are contingent upon Executive’s performance of
        Executive’s obligations under this Agreement.

       

      (f)         This Agreement may be executed in counterparts, each of which shall constitute an original, but all of which shall constitute one agreement.

       

      [Signatures on following page]

       

      
        19

        
          


      

      IN WITNESS WHEREOF, Executive and the undersigned duly authorized representative of the Company have executed this Agreement as of the date first above written.

       

      	 	
              EXECUTIVE

            
	 	 
	 	
              /s/ Kevin D’Amour, PhD

            
	 	
              Kevin D’Amour, PhD

            
	 	 
	 	
              BROOKLYN IMMUNOTHERAPEUTICS, INC

            
	 	 	 
	 	
              By:

            	
              /s/ Howard J. Federoff, MD, PhD

            
	 	 	
              Howard J. Federoff, MD, PhD

            
	 	 	
              Chief Executive Officer/President

            


       

      [Signature Page to Employment Agreement]

       

      
        20

        
          


      

      ADDENDUM A

       

      

      Job Duties

       

      	

            	•	
              Collaborates with the management team to set company research and scientific priorities to match the overall clinical mission and strategic goals of the company

            


      	

            	•	
              Stays updated on technological advances and industry trends to in scientific matters

            


      	

            	•	
              Provides recommendations for future projects, necessary technologies, and opportunities

            


      	

            	•	
              Provides leadership for the scientific activities in the company

            


      	

            	•	
              Communicates scientific experimental design and results to other managers and in collaboration with the CEO, as the CEO’s discretion, to the BOD

            


      	

            	•	
              Collaborates with the CFO, CMO, COO and VP R&D and provides leadership to develop budgets for research and development projects, including main focus and additional projects

            


      	

            	•	
              Approves spending for responsible teams within predetermined budgetary parameters

            


      	

            	•	
              Oversees, supports, and mentors all reporting personnel, maintaining a high level of commitment by and to employees

            


      	

            	•	
              Collaborates with the broader project team to ensure alignment of resource requirements in preclinical, clinical, and commercialization phases

            


      	

            	•	
              May participate, as needed, in regulatory strategy development, regulatory filings and meetings with regulatory agencies

            


      	

            	•	
              Responsible for drafting, submitting grants and progress reports for granting agencies that align with the priorities of the company.

            


      	

            	•	
              Participates in fundraising through presentations to investors and networking with contacts, as needed by the company

            


      	

            	•	
              Provides leadership for the scientific research agenda within the company and may be the point person, depending on the external entity, for outside collaborations with the company

            


      	

            	•	
              Provides leadership and collaborates with other R&D leadership and others in the orchestration of patent applications and scientific publications

            


      	

            	•	
              Collaborates as an management team member with manufacturing, business development, regulatory, finance, and clinical functions

            


      	

            	•	
              Chairs SAB, communicates with SAB, collates recommendations and disseminates for SAB meetings and encourages sub-meetings between SAB members and scientific and clinical staff, and endorses this work product be presented by sub-meeting
                leads to the SAB

            


      	

            	•	
              Responsible for identifying grant opportunities aligned with Brooklyn priorities, sharing these with the management team

            


      	

            	•	
              Partner with the CMO and other company clinical experts in external collaborations

            


      	

            	•	
              When a grant opportunity is endorsed, the CSO is responsible for the drafting the proposal along with other management colleagues and others within the company, and the submission of endorsed grants for non-dilutive funding aligned with
                company strategic priorities

            


      

      

      
        21

        
          


      

      	

            	•	
              Represent and support Brooklyn in interactions with the FDA, EMA, MHRA, and other regulatory bodies

            


      	

            	•	
              Provides leadership for the recruitment of qualified researchers, manages personnel in the span of reporting and evaluates their performance in compliance with company guidelines

            


      	

            	•	
              Supports the CEO, as needed, in representing the company at industry conferences

            


      	

            	•	
              Provides leadership, in collaboration with others, to ensure that the company’s best efforts are represented when presentations at scientific meetings are scheduled

            


      	

            	•	
              Collaborates with the management team, notably leadership of Manufacturing, the CMO, and regulatory consultants and/or Brooklyn regulatory leaders and to review changes in global regulations and industry practices for the development and
                approval of cell therapy products

            


      	

            	•	
              Maintain a high standard of internal scientific practices

            


      	

            	•	
              Sustain, along with other scientists, the company’s excellent scientific reputation

            


      	

            	•	
              May perform other duties and responsibilities as assigned

            


      

      

      
        22

        
          


      

      ADDENDUM B

       

      CALIFORNIA LABOR CODE SECTION 2870

      

      

      Section 2870 of the California Labor Code provides as follows:

      

      

      (a) Any provision in an employment agreement which provides that an employee shall assign, or offer to assign, any of his or her rights in an invention to his or her employer shall not apply to an
        invention that the employee developed entirely on his or her own time without using the employer’s equipment, supplies, facilities, or trade secret information except for those inventions that either:

       

      (1) Relate at the time of conception or reduction to practice of the invention to the employer’s business, or actual or demonstrably anticipated research or development of the employer; or

       

      (2) Result from any work performed by the employee for the employer.

       

      (b) To the extent a provision in an employment agreement purports to require an employee to assign an invention otherwise excluded from being required to be assigned under subdivision (a), the
        provision is against the public policy of this state and is unenforceable.

       

      
        23

        
          


      

      ADDENDUM D

       

      OUTSIDE ACTIVITIES OF EXECUTIVE

      

      

      For a period of 1-year from the effective date of the Agreement, the Company shall permit Executive to serve as a consultant to ViaCyte, Inc.  Executive agrees and acknowledges that he will not
        bring, use, or rely upon, or induce the Company to use or rely upon, any of ViaCyte, Inc.’s confidential or proprietary information or otherwise violate Section 9(c) of the Agreement.

      

      

      Executive’s work for ViaCyte, Inc. must not exceed 10 hours of time per calendar month.  Notwithstanding the foregoing, if Executive’s Supervisor determines, at his sole discretion, that
        Executive’s activities for ViaCyte, Inc. interfere with, conflict with, or otherwise harm the Company’s business, violates the terms of the Agreement, or breaches Executive’s fiduciary duties to the Company, Executive must immediately cease or
        decrease his activities for ViaCyte, Inc. at his Supervisor’s direction.

      

      

      

      

      
        24